Q1 2025 Zealand Pharma A/S Earnings Call Transcript
Key Points
- Zealand Pharma AS (ZLDPF) has entered a transformative collaboration with Roche on petrelintide, including co-development and co-commercialization rights with a 50/50 profit sharing in the US and Europe.
- The company has a strong financial position, with a cash equivalent and marketable securities totaling DKK8.5 billion as of March 31, 2025, and expects to receive a USD1.4 billion up-front payment from Roche.
- Zealand Pharma AS (ZLDPF) has a differentiated mid-to-late-stage obesity pipeline, with a focus on amylin analogs, which have shown potential for effective weight management.
- The company has strengthened its organization by hiring key personnel, including a new Chief Scientific Officer and a medical advisor in obesity, to drive its research and development efforts.
- Zealand Pharma AS (ZLDPF) is committed to advancing its rare disease programs, with clear paths forward for its late-stage programs and ongoing efforts to secure partnerships.
- The company faces geopolitical and market uncertainties, which could impact its operations and growth plans.
- There are challenges in ensuring patient adherence to weight management therapies, as many patients struggle to stay on current treatments due to side effects.
- Zealand Pharma AS (ZLDPF) is still in the early stages of its obesity market evolution, with only about 2% of eligible patients currently on pharmacotherapy.
- The company is awaiting an inspection classification upgrade of its third-party manufacturer's facility, which affects the resubmission of its dasiglucagon application.
- There is significant competition in the amylin analog space, with other companies developing similar therapies, which could impact Zealand Pharma AS (ZLDPF)'s market position.
Good day and thank you for standing by. Welcome to the Zealand Pharma Results for Q1 2025 conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to have the conference over to your speaker today, Adam Lange, Vice President, Investor Relations. Please go ahead.
/- -
Thank you, operator, and thank you to everyone for joining us today to discuss Zealand Pharma's results for the first three months of 2025. You can find the related company announcements on our website at zealandpharma.com. As described on slide 2, I caution listeners that during this call, we will be making forward-looking statements that are subject to risks and uncertainties.
Turning to slide 3 and the agenda. With me today are the following members of Zealand Pharma's management team. Adam Steensberg, President and Chief Executive Officer; Henriette Wennicke, Chief Financial Officer; and David Kendall, Chief Medical
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
